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Edited by Richard MaraisAbstract The FOXM1 forkhead proteins, originally identiﬁed
as M-phase phosphoproteins, are proliferation-associated tran-
scriptional regulators involved in cell cycle progression, genetic
stability and tumorigenesis. Here we demonstrate that Cyclin-
dependent kinases regulate the transcriptional activity of
FOXM1c. This is independent of an N-terminal negative regula-
tory domain and of the forkhead DNA binding domain. Instead
we mapped the responsive sites in the transactivation domain. A
combination of three phosphorylation sites mediates the Cyclin E
and Cyclin A/CDK2 eﬀects. Our ﬁndings provide evidence for a
novel Cyclin E/CDK2 substrate that functions in cell cycle con-
trol.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cyclin A1. Introduction
The forkhead box (FOX) protein family of transcriptional
regulators are involved in controlling many distinct aspects
of cell behavior [1,2]. FOXM1, originally identiﬁed as MPP2,
Trident, HFH-11, and WIN [3–7], is expressed in proliferating
but not resting or diﬀerentiated cells [8]. FOXM1 promotes cell
cycle progression by aﬀecting both the G1 to S-phase and the
G2 to M-phase transition. In addition FOXM1 is an impor-
tant regulator of chromosomal stability. These eﬀects are med-
iated by FOXM1-dependent regulation of target genes that
include several cyclin genes and the CENP-F gene [9–12]. In
addition to the cyclin genes that are activated, the expression
of the CDK inhibitors p21WAF1 and p27KIP1 are downregu-
lated, together providing an explanation for the ability of
FOXM1 to stimulate cell cycle progression. Furthermore
forced FOXM1 expression in the liver stimulates hepatocyte
proliferation in response to partial hepatectomy while lack of
FOXM1 results in a delay of liver regeneration [6,13,14]. The
important role of FOXM1 for hepatocyte proliferation is fur-
ther documented by the ﬁnding that this factor is necessary for
the development of hepatocellular carcinoma [15]. Recently
over-expression of FOXM1 has been observed in human mam-
mary carcinoma and in breast cancer cell lines [10]. While these*Corresponding author. Fax: +49 241 8082427.
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doi:10.1016/j.febslet.2006.02.021studies deﬁne FOXM1 as a proliferation-associated factor, its
down-regulation or knock-out results not simply in inhibition
of proliferation but in chromosomal instability [10,12,16]. To-
gether these studies deﬁne FOXM1 as an important regulator
of cell proliferation and genetic stability.
The progression of cells from the G1 into the S-phase of
the cell cycle is controlled by D-type Cyclins associated with
CDK4 and CDK6 and by Cyclin E with CDK2 and CDK1
[17,18]. Pocket proteins are the main substrates of Cyclin
D/CDK complexes. Indeed these kinases are not required
for S-phase entry in retinoblastoma tumor suppressor protein
(Rb)-negative cells. In contrast, Cyclin E complexes are
essential for S-phase progression also in Rb-negative cells
[19]. This indicates that Cyclin E/CDK2 targets additional
critical substrates other than Rb. These include p27, Nucleo-
phosmin, Cdc6, NPAT, CP110 and hHR6A that mediate at
least in part the eﬀects of Cyclin E/CDK2 on centrosome
duplication, initiation of replication and S-phase speciﬁc gene
transcription [20–25]. The inappropriate activation of these
CDKs, including increased expression of Cyclin E, is associ-
ated with tumor formation [26,27]. Additionally, the Cyclin
E/CDK2 kinase is activated in response to several oncopro-
teins, including c-Myc and the adenoviral E1A protein, fur-
ther supporting a role of this kinase in tumorigenesis
[28,29]. During S- and G2-phase Cyclin A/CDK2 complexes,
in part overlapping with Cyclin E/CDK2, are important to
regulate further progression in the cell cycle and many of
the Cyclin E/CDK2 substrates are also phosphorylated by
Cyclin A/CDK2.
FOXM1 was originally identiﬁed as a protein that reacts
with the monoclonal antibody MPM-2 that recognizes phos-
pho-epitopes in mitotic cells [3]. This suggested that the phos-
phorylation of FOXM1 is cell cycle and/or signal regulated.
Indeed recent evidence suggests phosphorylation-dependent
regulation of FOXM1 [30,31]. We identiﬁed FOXM1c in a
yeast two-hybrid screen as an interaction partner for the
human papilloma virus 16 E7 protein and cloned one of
the several splice variants referred to as FOXM1c [4]. E7 in-
duces S-phase in part by binding to the Rb protein, thereby
blocking interaction with E2F transcription factors. However
additional activities of E7 are required to promote S-phase
entry [32]. These ﬁndings, together with the fact that FOXM1
contains several potential CDK phosphorylation sites, led us
to hypothesize that Cyclin E/CDK2 might regulate FOXM1c.
Indeed we observed that the transcriptional activity of
FOXM1c is stimulated in response to Cyclin E/CDK2. This
was dependent on the C-terminal transactivation domain.
We identiﬁed a combination of three phosphorylation sites
that are phosphorylated by Cyclin E/CDK2 and mediate
the transcriptional response.blished by Elsevier B.V. All rights reserved.
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2.1. Cell culture, plasmids and transient transfection assays
Cultivation and transfection of NIH3T3, RK-13, HEK293, HeLa
and COS7 cells has been described previously [4]. For serum stimula-
tion experiments, transiently transfected NIH3T3 cells were starved in
0.1% fetal calf serum (FCS) for 24 h prior to stimulation with 10%
FCS. S-phase progression was monitored by incubating the cells in
100 lM bromodeoxyuridine (BrdU) for 1 h and staining with an
anti-BrdU antibody coupled to ﬂuoresceine (Boehringer, Mannheim).
Roscovitine (25 lM) was added to the transfected cells 6 h prior to
harvesting. The expression plasmid for FOXM1c and Gal4-FOXM1c
and the reporter plasmids (MBS)3-mintk-luc and (Gal4)4-mintk-luc
have been described previously [4]. FOXM1c mutants were cloned
using standard techniques. Point mutations were generated using
Quick-change (Stratagene). Plasmids encoding Cyclin E, Cyclin A,
CDK2, CDK2dn, p27KIP1, and p21WAF1 were kindly provided by R.
Bernards. FOXM1c and mutants were detected using SC-502 (Santa
Cruz) that recognizes the C-terminus of the protein. For Western blots
cells were lysed in F-buﬀer (10 mM Tris–HCl, pH 7.05, 50 mM NaCl,
30 mM Na4P2O7, 50 mM NaF, 5 lM ZnCl2, 100 lMNa3VO4, 1% Tri-
ton X-100, 1 mM PMSF, 5 U/ml a2-macroglobulin, 2.5 U/ml pepstatin
A, 2.5 U/ml leupeptin, 0.15 mM benzamidin) as described before [33].
2.2. Preparation of active cyclin E/CDK2 complexes, kinase assays and
metabolic labeling
Expression and puriﬁcation of human cyclin E/CDK2 complexes
from insect cells infected with recombinant baculoviruses were carried
out as described [34]. For kinase assays FOXM1c and mutants were
expressed in COS7 cells, immunoprecipitated and incubated with Cy-
clin E/CDK2 in kinase buﬀer (50 mM HEPES, pH 7.5, 10 mMMgCl2,
0.01% Tween-20, 10 mM NaF, 10 mM b-glycerophosphate, 1 mM
orthovanadate, 0.01 % BSA) containing 25 lM ATP (speciﬁc activity
2 mCi/lmol) for 30 min. For in vivo labeling, COS7 cells were tran-
siently transfected with plasmids encoding FOXM1c or FOXM1c
(T599A/T610A/S637A) together with CDK2 and Cyclin E. Two days
post transfection, cells were metabolically labeled in phosphate-free
DMEM supplemented with 10% dialyzed FCS, 20 mM sodium bicar-
bonate, 18 mM HEPES, pH 7.5, and 2 mCi 32P-orthophosphate for
2 h and lysed in RIPA buﬀer (10 mM Tris–HCl, pH 7.4, 150 mM
NaCl, 1% NP-40, 1% deoxycholate, 0.1% SDS, 7 lg/ml aprotinin
and 20 mM b-glycerophosphate).
2.3. GST pull-down assays and phosphatase treatment
The FOXM1c proteins were immunoprecipitated and analyzed by
SDS–PAGE. GST pull-down assays were performed as described pre-
viously [4]. For phosphatase treatment FOXM1c was immunoprecipi-
tated using SC-502 from F-buﬀer lysates of HeLa cells. The
immunoprecipitates were washed three times in F-buﬀer, once in PPase
buﬀer (0.5 M Tris, pH 8.5, 1 mM EDTA) and then incubated in 20 ll
PPase buﬀer with 1U calf intestinal phosphatase. The proteins were
analyzed by SDS–gel electrophoresis and Western blotting.3. Results
3.1. FOXM1c is activated by Cyclin E/CDK2
To address whether Cyclin E/CDK2 could aﬀect FOXM1c
transcriptional activity, we performed reporter gene assays.
We observed that Cyclin E/CDK2 strongly enhanced
FOXM1c-dependent transcription of the (MBS)3-mintk-luc re-
porter gene that contains three binding sites for FOXM1c
while Cyclin E or CDK2 alone had little eﬀect (Fig. 1A). A re-
porter gene without binding sites was not activated. The co-
expression of a kinase dead mutant of CDK2 (CDK2dn) did
not activate but rather repressed FOXM1c transactivation
indicating that CDK2 kinase activity is required for basal as
well as stimulated FOXM1c activity (Fig. 1A). In addition
the Cyclin E/CDK2 inhibitors p21WAF1 and p27KIP2 abolished
and roscovitine, a CDK2 inhibitor, suppressed the Cyclin E/CDK2 eﬀect on FOXM1c-dependent transactivation (Fig. 1B
and C). Furthermore a Gal4-FOXM1c fusion protein was also
stimulated by Cyclin E/CDK2 and repressed by p27KIP2 sug-
gesting that the kinase is not targeting the DNA binding do-
main (Fig. 1D). Together these ﬁndings deﬁne Cyclin E/
CDK2 as an eﬃcient activator of the transcriptional activity
of FOXM1c.3.2. Cell cycle regulation of FOXM1c(190–763)
As demonstrated above the transcriptional activity of
FOXM1c is strongly stimulated by Cyclin E/CDK2, which is
activated in the late G1-phase. Therefore we addressed
whether FOXM1c might be activated at the G1 to S-phase
border. NIH3T3 cells were transiently transfected with an
expression plasmid for FOXM1c(190–763) and the (MBS)3-
mintk-luc reporter gene and serum starved for 24 h prior to
stimulation with 10% FCS. An induction of FOXM1c(190–
763)-dependent transactivation was observed when cells en-
tered S-phase as determined by BrdU incorporation (Fig. 2A
and B). Similar experiments were performed with FOXM1c.
However due to the low activity of the full length protein only
small activations were measured after serum stimulation (data
not shown). These observations are consistent with an activa-
tion of FOXM1c by endogenous Cyclin E/CDK2.3.3. The C-terminal transactivation domain is important to
mediate the Cyclin E/CDK2 eﬀect
FOXM1c possesses 18 Ser/Thr-Pro motifs that represent po-
tential Cyclin E/CDK2 modiﬁcation sequences. Particularly
obvious are two clusters of potential sites in the C-terminal half
of the protein (Fig. 4A). In order to identify Cyclin E/CDK2
responsive regions in FOXM1c deletion mutants were gener-
ated. Truncation of the N-terminal 189 amino acids resulted
in a protein, FOXM1c(190–763), that showed signiﬁcantly en-
hanced transcriptional activity (Fig. 3A). Since this protein
was expressed equally to the wild-type FOXM1c (Fig. 3B),
the N-terminal domain represents a negative regulatory domain
(NRD, Fig. 3). Although two potential phosphorylation sites
are deleted in FOXM1c(190–763), this protein was still eﬃ-
ciently activated by Cyclin E/CDK2 (Fig. 3A). Both the basal
and the Cyclin E/CDK2-stimulated activity of FOXM1c(190–
763) was eﬃciently repressed by p27KIP2 suggesting that endog-
enous CDK2 activity is required for transactivation by
FOXM1c(190–763) (Fig. 3C). In contrast deletion of the acidic
transactivation domain (TAD) near the C-terminus in
FOXM1c(1–588/745–763) completely abolished both transacti-
vating activity and Cyclin E/CDK2 responsiveness, indicating
that the TAD is important for the Cyclin E/CDK2 eﬀect
(Fig. 3A). Deletion of the N-terminal domain in addition to
the TAD in FOXM1c(190–588/745–763) was not suﬃcient to
activate the transcription factor, despite eﬃcient expression of
this mutant, and this mutant remained insensitive to Cyclin E/
CDK2 (Fig. 3B and data not shown). FOXM1c(1–348/575-
763) with a deletion of a central portion was poorly expressed
(Fig. 3B). Nevertheless this protein was activated by Cyclin E/
CDK2 with a similar potency as FOXM1c and FOXM1c
(190–763) (Fig. 3A). Thus neither the N-terminal NRD nor
the central region of FOXM1c is important to mediate the
Cyclin E/CDK2 eﬀect. Instead the C-terminal quarter of the
protein that includes the TAD appears to be the target of this
kinase.
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Fig. 1. FOXM1c-dependent transactivation is stimulated by Cyclin E/CDK2. (A) RK-13 cells were transiently transfected with the mintk-luc or
(MBS)3-mintk-luc reporter plasmids (2 lg) and expression plasmids encoding FOXM1c, Cyclin E (0.5 lg), CDK2 (0.5 lg) and CDK2dn (0.5 lg) as
indicated. A representative experiment performed in triplicates is shown. (B) Reporter gene assays were performed as under A. Expression plasmids
encoding FOXM1c (2 lg), Cyclin E (0.2 lg), CDK2 (0.2 lg), p27KIP1 (0.5 lg) and p21WAF1 (0.5 lg) were included as indicated. A representative
experiment is shown. (C) Experiments were performed as in B. Roscovitine was added to a ﬁnal concentration of 25 lM 6 h prior to harvesting. The
mean values and standard deviations of three independent experiments are displayed. (D) RK-13 cells were transiently transfected with the (Gal4)4-
mintk-luc reporter plasmid (2 lg) and expression plasmids encoding Gal4-FOXM1c (2 lg), Cyclin E (0.5 lg), CDK2 (0.5 lg) and p27KIP1 (0.5 lg) as
indicated. A representative experiment performed in duplicates is shown.
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regulation of FOXM1c
FOXM1c possesses 18 potential phosphorylation sites that
fulﬁll the minimal consensus sequence (Fig. 4A). Some of
these sites were considered more important than others be-
cause of a basic amino acid at position +3 or because the
sites are conserved across species (see Fig. 4A for details).
This information together with the analysis of FOXM1c
mutants (Fig. 3) was used to address the role of individual
potential Cyclin E/CDK2 phosphorylation sites. We mutage-
nized Ser or Thr residues, either single or in combination, inFOXM1c and tested these mutants for their response to Cy-
clin E/CDK2 in reporter gene assays (summarized in
Fig. 4A). None of the single mutations aﬀected the Cyclin
E/CDK2 response (Fig. 4A and B and Supplementary
Fig. 1A). This included the only potential phosphorylation
site located in the forkhead domain (Ser331). This together
with the analysis of the Gal4-FOXM1c fusion protein
(Fig. 1D) suggested that the DNA binding domain is not reg-
ulated by Cyclin E/CDK2. However combinations of point
mutations that included Thr600, Thr611 and Ser638 showed
a substantially reduced response to Cyclin E/CDK2
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Fig. 2. FOXM1c(190–763) is activated during G1 to S-phase transi-
tion. (A) NIH3T3 cells were transiently transfected with the (MBS)3-
mintk-luc reporter plasmid (2 lg) and an expression plasmid encoding
FOXM1c(190–763) (2 lg). The cells were then serum starved for 24 h,
restimulated with 10% FCS and luciferase was measured at the time
points indicated. The mean values and standard deviations of four
independent experiments are displayed. (B) Serum-starved NIH3T3
cells were stimulated with 10% FCS and BrdU-pulse labeled for 1 h
prior to harvesting at the times indicated. The cells were ﬁxed and
stained for BrdU incorporation. The percent of BrdU-positive cells is
given.
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tion of 2 of the 3 sites reduced the Cyclin E/CDK2 response
with FOXM1c(T600A/T611A) and FOXM1c(T611A/S638A)
while little or no eﬀect was seen with FOXM1c(T600A/Fig. 3. Regulation by Cyclin E/CDK2 requires the transactivation domain
(MBS)3-mintk-luc reporter plasmid (2 lg) and expression plasmids encoding
indicated. The mean values and standard deviations of three independent expe
mutants employed is shown. NRD, negative regulatory domain; FKH, forkhe
acids. (B) The expression of FOXM1c and mutants was determined by W
Transfections were performed as in A. Plasmids encoding FOXM1c(190–76
used as indicated. Mean values and standard deviations of four independentS638A) (Fig. 4A and Supplementary Fig. 1A). This indicated
that Thr611 was particularly important to mediate the Cyclin
E/CDK2 eﬀect. However this site was not suﬃcient for the
response to Cyclin E/CDK2 since FOXM1c(T611A) was acti-
vated by the kinase to wild-type levels (Fig. 4B). Since many
Cyclin E/CDK2 sites are also used by Cyclin A/CDK2, we
tested for the response of FOXM1c and FOXM1c(T600A/
T611A/S638A) to Cyclin A/CDK2. This kinase led to a ro-
bust stimulation of FOXM1c but the triple mutant protein
was signiﬁcantly less responsive, comparable to the ﬁndings
obtained with Cyclin E/CDK2 (Fig. 4C). It is worth pointing
out that Cyclin D1/CDK4 also stimulated FOXM1c-depen-
dent transactivation but this could not be attributed to any
of the potential sites mutated in this study (data not shown).
Furthermore Cyclin B1/CDK1 did not stimulate FOXM1c
(data not shown). In summary our ﬁndings deﬁne 3 sites,
Thr600, Thr611 and Ser638, that mediate the majority of
the Cyclin E/CDK2 and the Cyclin A/CDK2 eﬀect on
FOXM1c.
3.5. FOXM1c is phosphorylated by Cyclin E/CDK2
To assess whether Thr600, Thr611 and Ser638 are direct
CDK2 targets, FOXM1c and mutants thereof were immuno-
precipitated from lysates of transiently transfected cells and
used as substrates for recombinant Cyclin E/CDK2
(Fig. 4D). Wild-type FOXM1c was readily phosphorylated
while FOXM1c(1–480) and FOXM1c(1–588/745–763) were
poorly phosphorylated consistent with the lack of Thr600,
Thr611 and Ser638 in these two proteins. Furthermore
FOXM1c(T600A/T611A/S638A) was also poorly phosphory-
lated, strongly suggesting that these 3 sites are targeted
in vitro by Cyclin E/CDK2 (Fig. 4D and Supplementary
Fig. 1B). Equal expression was veriﬁed by analyzing an ali-
quot of these immunoprecipitates by Western blottingof FOXM1c. (A) RK-13 cells were transiently transfected with the
FOXM1c or mutants (2 lg), Cyclin E (0.5 lg) and CDK2 (0.5 lg) as
riments are displayed. A schematic representation of FOXM1c and the
ad domain; TAD, transactivation domain. The numbers refer to amino
estern blot analysis of F-buﬀer extracts using SC-502 antibodies. (C)
3) (2 lg), Cyclin E (0.5 lg), CDK2 (0.5 lg) and p27KIP1 (0.5 lg) were
experiments are shown.
Fig. 4. Cyclin E/CDK2 phosphorylation sites in FOXM1c. (A) The sequences of the 18 potential phosphorylation sites are given. The amino acids
deﬁning optimal Cyclin E/CDK2 sites are boxed. Amino acids conserved between human, mouse and rat are in bold. The eﬀects of Cyclin E/CDK2
on mutant FOXM1c-dependent transactivation are summarized: +, >75% activity, (+), 25–75% activity, , <25% activity as compared to the wild-
type protein. na, not analyzed. A schematic representation of FOXM1c is shown with the 18 potential phosphorylation sites indicated with
arrowheads. The sites identiﬁed as relevant for Cyclin E/CDK2 responsiveness are marked with P. (B) RK-13 cells were transiently transfected with
the (MBS)3-mintk-luc reporter plasmids (2 lg) and expression plasmids encoding FOXM1c or mutants (2 lg), Cyclin E (0.2 lg) and CDK2 (0.2 lg)
as indicated. A representative experiment is shown. In the insert the expression of the FOXM1c mutants analyzed by Western blotting is shown. (C)
The transfections were performed as in B with the exception that Cyclin A was co-expressed instead of Cyclin E. (D) The indicated FOXM1c proteins
were expressed transiently in COS7 cells, immunoprecipitated with SC-502 and phosphorylated using recombinant Cyclin E/CDK2. The upper panel
shows an autoradiogram of the phosphorylated proteins, the lower panel a Western blot of the immunoprecipitated proteins. The relevant proteins
are indicated by arrowheads. Phosphorylation of recombinant GST-tagged Cyclin E is marked with an arrowhead. Immunoglobulin heavy chains
seen on the Western blot are labeled with IgH. (E) Pull-down assays with GST and GST-Cyclin E were performed with in vitro transcribed and
translated FOXM1c and FOXM1c(T600A/T611A/S638A). The left panel shows a Coomassie blue (CB) stained gel of the GST and GST-Cyclin E
proteins used. The autoradiograms (35S) show 10% of the input, the bound material to GST and to GST-Cyclin E. (F) FOXM1c and
FOXM1c(T600A/T611A/S638A) were transiently expressed in COS7 cells in the presence of Cyclin E/CDK2. The cells were labeled with 32P-
orthophosphate and the FOXM1c proteins immunoprecipitated (upper panel). The expressed FOXM1c proteins were analyzed by Western blotting
(lower panel). The arrow head indicates a protein species with slower mobility on SDS–PAGE. (G) FOXM1c and FOXM1c(T600A/T611A/S638A)
were transiently expressed in HEK293 cells in the presence or absence of Cyclin E, CDK2 or CDK2dn, as indicated. The mobility of the FOXM1c
proteins was assessed upon SDS–gel electrophoresis and Western blotting. (H) Endogenous FOXM1c was immunoprecipitated from HeLa cells that
were treated with 200 lM hydroxyurea for 16 h and with 25 lM roscovitine for 3 h prior to harvesting in F-buﬀer. The immunoprecipitates were then
either mock or phosphatase (PPase) treated and the resulting FOXM1c proteins analyzed by Western blotting.
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FOXM1c as well as FOXM1c(T600A/T611A/S638A) inter-
acted with GST-Cyclin E but not with GST in pull-down as-
says, indicating that the interaction with Cyclin E is
independent of the phosphorylation sites (Fig. 4E). Cyclin
E was also co-immunoprecipitated with FOXM1c from cell
lysates albeit weakly as expected for a substrate/enzyme inter-
action (data not shown). This suggests that FOXM1c can di-
rectly interact with Cyclin E/CDK2 and supports the notion
that FOXM1c is a substrate of this kinase. To deﬁne whether
the FOXM1c(T600A/T611A/S638A) is less eﬃciently phos-
phorylated than the wild-type protein in cells, FOXM1c
and the triple mutant were co-expressed with Cyclin E/
CDK2 in COS7 cells and metabolically labeled with 32P-
orthophosphate. The phosphorylation of the mutant protein
was only weakly reduced compared to the wild-type protein
(Fig. 4F). This suggested that FOXM1c is an extensively
phosphorylated protein and the loss of the 3 Cyclin E/
CDK2 sites has only a minimal eﬀect on the overall phos-phorylation of this protein. However we noted that the signal
from wild-type FOXM1c extended to higher apparent molec-
ular weight than FOXM1c(T600A/T611A/S638A). In support
a slower migrating protein species were identiﬁed on Western
blots of the wild-type but not the mutant protein (Fig. 4F).
This ﬁnding was extended by expressing FOXM1c and
FOXM1c(T600A/T611A/S638A) in the presence or absence
of Cyclin E/CDK2 or CDK2dn in HEK293 cells. Again the
wild-type but not the mutant protein revealed a shift to high-
er apparent molecular weight in the presence of Cyclin E/
CDK2 (Fig. 4G). Finally we prepared lysates of HeLa cells
arrested in S-phase, immunoprecipitated FOXM1c and trea-
ted the proteins with calf intestinal phosphatase. This resulted
in an increase in the mobility of FOXM1c, indicating that the
loss of phosphate signiﬁcantly reduced the apparent molecu-
lar weight (Fig. 4H). This is consistent with the altered mobil-
ity in response to Cyclin E/CDK2 phosphorylation. Together
these studies deﬁne three CDK2 phosphorylation sites that
regulate FOXM1c transcriptional activity.
Fig. 4 (continued)
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Our ﬁndings demonstrate that FOXM1c is a direct target
of Cyclin E/CDK2 and Cyclin A/CDK2 kinase complexes.
Phosphorylation by these kinases results in the activation of
the transcriptional activity of FOXM1c. Thus this transcrip-
tion factor is an additional mediator of the activities of
CDK2 kinases in controlling S- and G2-phase progression.
Recent studies demonstrate that a reduction or the absence
of FOXM1 severely aﬀects genomic stability. The loss of
FOXM1 results in a mitotic block with frequently misaligned
chromosomes and causes centrosome ampliﬁcation [10,12].
This in turn leads to mitotic catastrophe and subsequently
inhibition of proliferation. Mechanistically this is explained
by the ability of FOXM1 to regulate genes, including cyclin
B1 and B2 and CENP-F, that encode proteins relevant for
G2-M-phase progression and that are associated with the mi-
totic checkpoint [10–12]. Thus it is possible that FOXM1 is
one of the factors that links early cell cycle regulatory events
through its regulation by CDK2 complexes to the control of
mitosis.
A recent study has shown that FOXM1b, an alternative
splice variant of FOXM1, revealed extensive phosphoryla-
tion that was suggested to be mediated by several diﬀerent
kinases [31]. Thr596 in FOXM1b, the amino acid that
corresponds to Thr611 in FOXM1c, was also identiﬁed asa cell cycle regulated phosphorylation site that mediates
cofactor binding and transcriptional activity [31]. Although
mutation of Thr611 alone was not suﬃcient to aﬀect the re-
sponse of FOXM1c to CDK2 complexes, the ﬁndings sug-
gest that both FOXM1b and FOXM1c are phosphorylated
at the corresponding amino acid in the TAD by CDKs. In
contrast to FOXM1b, at least 3 amino acids had to be
mutated in FOXM1c for a substantial reduction in tran-
scriptional activity. This oﬀers the possibility that the
diﬀerent splice variants show distinct responses to individual
kinase activities, an aspect that will be important to study in
the future. Together it appears from our ﬁndings and pub-
lished observations that FOXM1, an important regulator
of cell cycle progression, is controlled by Cyclin E/CDK2
and most likely a number of additional kinases, at least
some of which are cell cycle regulated [3,31]. Indeed a recent
study demonstrates that the Raf/MEK/MAPK signal trans-
duction pathway regulates FOXM1c, which links this pro-
tein to receptor-mediated control of cell behavior [30].
Together with the ﬁndings that FOXM1 is necessary for
the development of hepatocellular carcinoma [15] and that
FOXM1 is over-expressed in mammary tumors [10], it
appears that this transcription factor is critical to relay
information from external and internal signal transduction
pathways to the cell cycle machinery and by this aﬀecting
genomic stability.
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